-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Downgrades Surgery Partners to Neutral, Raises Price Target to $23.5

Benzinga·10/28/2026 21:03:24
Listen to the news
UBS analyst A.J. Rice downgrades Surgery Partners (NASDAQ:SGRY) from Buy to Neutral and raises the price target from $21 to $23.5.